BackAvalo Therapeutics Overview
Avalo Therapeutics Inc

Avalo Therapeutics Target Price

See Avalo Therapeutics's analyst price targets ($39) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$16.07

Average Target Price

$38.67140.6% upside

3 analysts in the last 4 months

High: $48 | Low: $30

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-07Guggenheim$48198.7% upsideOpen
2026-08-07H.C. Wainwright$3086.7% upsideOpen
2026-07-06Leerink Partners$38136.5% upsideOpen
2026-05-14Wedbush$34111.6% upsideOpen
2026-05-14Mizuho Securities$45180% upsideOpen
2026-05-14H.C. Wainwright$35117.8% upsideOpen
2026-05-11Piper Sandler$60273.4% upsideOpen
2026-05-06BTIG$58260.9% upsideOpen
2026-04-08Wolfe Research$48198.7% upsideOpen
2026-02-02Guggenheim$50211.1% upsideOpen
2025-12-17Mizuho SecuritiesJoseph Catanzaro$39142.7% upsideOpen
2025-09-17H.C. Wainwright$2555.6% upsideOpen
2025-03-25JefferiesKambiz Yazdi$2343.1% upsideOpen
2024-04-16OppenheimerLeland Gershell$35117.8% upsideOpen

Avalo Therapeutics (AVTX) FAQ

Avalo Therapeutics's target price stands at $39. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $39 for AVTX implies 140.6% upside versus today's price ($16.07). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Avalo Therapeutics's target price evolved across reporting periods, while the comparison chart places AVTX next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Avalo Therapeutics's reading of $39 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.